BioNTech SE (BioNTech SE) Ending Cash Position : $12,719 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is BioNTech SE Ending Cash Position?

BioNTech SE's Ending Cash Position for the quarter that ended in Dec. 2023 was $12,719 Mil.

BioNTech SE's quarterly Ending Cash Position declined from Jun. 2023 ($15,348 Mil) to Sep. 2023 ($14,403 Mil) and declined from Sep. 2023 ($14,403 Mil) to Dec. 2023 ($12,719 Mil).

BioNTech SE's annual Ending Cash Position increased from Dec. 2021 ($1,913 Mil) to Dec. 2022 ($14,698 Mil) but then declined from Dec. 2022 ($14,698 Mil) to Dec. 2023 ($12,719 Mil).

BioNTech SE Ending Cash Position Historical Data

The historical data trend for BioNTech SE's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE Ending Cash Position Chart

BioNTech SE Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

576.78

1,472.26

1,912.66

14,698.20

12,719.41

BioNTech SE Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Ending Cash Position	Get a 7-Day Free Trial															14,698.20	13,002.03	15,348.43	14,403.20	12,719.41

BioNTech SE Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

BioNTech SE's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	15130.97	+	-2411.559
	=	12,719

BioNTech SE's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	14717.339	+	-1997.928
	=	12,719

BioNTech SE Ending Cash Position Related Terms

Thank you for viewing the detailed overview of BioNTech SE's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNTech SE (BioNTech SE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (NAS:BNTX) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

BNTX:Mexico 0A3M:UK 22UA:Germany B1NT34:Brazil BNTX:Austria

Address

An der Goldgrube 12, Mainz, RP, DEU, D-55131

Website

https://www.biontech.de

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.